1. Mrs. Schwartzman is a 52-year-old patient with schizophrenia and no established history of depression. When meeting with the PMHNP, she presents with apathy and withdrawn social behavior, and she reports a loss of joy from enjoyable activities. What does the PMHNP infer from this encounter with the patient? A. An underlying depressive disorder B. […]
What does the PMHNP infer from this encounter with the patient? Read More »
1. Which statement made by the PMHNP exemplifies correct teaching of physiological effects in the body? A. Muscarinic antagonists are more likely to cause decreased prolactin levels. B. D2 antagonists decrease the likelihood of EPS symptoms. C. D2 antagonism is linked to antidepressant properties. D. D2 partial agonists are associated with increased efficacy in treating
1. The PMHNP is assessing a patient who has cirrhosis of the liver and anticipates that the patient will be prescribed an antipsychotic. Which medication does the PMHNP suspect will be ordered for this patient? A. Quetiapine B. Paliperidone C. Lurasidone D. Clozapine Place Your Order Here!
Which medication does the PMHNP suspect will be ordered for this patient? Read More »
1. The PMHNP is caring for a patient who is taking antipsychotics heard the psychiatrist tell the patient that the patient would be placed on a different antipsychotic agent. Which of the following requires the longest transition time for therapeutic benefit? Olanzapine to clozapine B. Asenapine to Risperidone C. Aripripazole to ziprasidone D. Aripripazole to
Which of the following requires the longest transition time for therapeutic benefit? Read More »
1. The PMNHP is assessing a 29-year-old patient who takes antipsychotics that block D2 receptors. What patient teaching should the PMHNP include related to the possible side effects of this type of drug? A. Hypersexuality B. Amenorrhea C. Dystonia D. Tardive dyskinesia Place Your Order Here!
1. A patient is diagnosed with schizophrenia. What increases the patient’s potential to mediate the cognitive symptoms of the disease? A. Achieving underactivity of the mesocorticol projections to the prefrontal cortex B. Achieving overactivity of the mesocorticol projections to the ventromedial prefrontal cortex C. Achieving underactivity of the mesocortical projections to the ventromedial prefrontal cortex
What increases the patient’s potential to mediate the cognitive symptoms of the disease? Read More »
1. The PMHNP is caring for a patient with schizophrenia and is considering a variety of treatment approaches. The PHMNP selects a viable treatment that is consistent with the “dopamine hypothesis of schizophrenia.” What action does the PMHNP anticipate this treatment having on the patient? A. Blocking the release of dopamine facilitates the onset of
What action does the PMHNP anticipate this treatment having on the patient? Read More »
1. Mrs. Trevor is a 44-year-old patient who does not have a diagnosis of schizophrenia but occasionally reports symptoms of psychosis, followed by severe fatigue. Mrs. Trevor inquires about the use of amphetamines to help with her energy levels. Which response made by the PMHNP is most appropriate? A. “Amphetamines may help you, as they
Which response made by the PMHNP is most appropriate? Read More »
1. Mr. McCullin is 64 years old with Parkinson’s disease. The PMHNP caring for Mr. McCullin wants to start him on a dopamine agonist to help manage and treat his condition. The PHMNP selects this agent because of which action it has on patients like Mr. McCullin? A. Dopamine is terminated through multiple mechanisms. B.
1. A patient has been treated with a number of novel psychotropic drugs. How is it theoretically possible to identify cognitive improvement in the patient using neuropsychological assessment batteries after the pharmacologic therapy? I did not have this question A. Obtaining raw normative metrics and using them to assess functionality B. Having the patient report